Table 1.

Summary of Individual Studies Analyzed in This Manuscript

Study	Laboratory	Study Design	Results Presented
1	A	weekly ASO injections, from 2/3–7 weeks of age (WT ASO-Ctrl, Mtm1−/y ASO-Ctrl, Mtm1−/y DYN101-m), 25 mg/kg	Figures 1, 2, 3, 4; Figures S1, S4, S5
2	B	as for (1), 2nd independent cohort, 25 mg/kg	Figure 4; Figures S4 and S5
3	A	single ASO injection at 3 weeks, analysis 1, 2, 4, 8 weeks post injection (WT ASO-Ctrl, Mtm1−/y ASO-Ctrl, Mtm1−/y DYN101-m), 25 mg/kg	Figure 2; Figures S2, S4, S5
4	B	genetic cross cohort, analyzed at 2 weeks (WT, Mtm1−/y, Mtm1−/yDnm2+/−)	Figure 4; Figures S4 and S5
5	A	weekly ASO injections, from 5 to 12 weeks of age (WT ASO-Ctrl, Mtm1−/y ASO-Ctrl, Mtm1−/y DYN101-m), 6.25, 12.5, and 25 mg/kg	Figure 2; Figure S3
6	A	weekly ASO injections, from 8 to 12 weeks of age (WT ASO-Ctrl, Dnm2R465W/+ ASO-Ctrl, Dnm2R465W/+DYN101-m), 25 mg/kg	Figure S6